Drug Profile


Alternative Names: LY 335979; RS 33295; RS 33295-198; Zosuquidar trihydrochloride

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Kanisa Pharmaceuticals
  • Class Antineoplastics; Dibenzocycloheptenes; Quinolines
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 11 Dec 2007 Interim safety and efficacy data from a phase I/II trial in Acute myeloid leukaemia presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)
  • 31 Oct 2005 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In the elderly) in USA (IV)
  • 17 Aug 2000 Phase-II clinical trials for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top